Evidence map›Paper›PMID 29498659›Full record

ArticleMolecules (Basel, Switzerland)2018

Investigation of an

Susann Schröder, Barbara Wenzel, Winnie Deuther-Conrad, Rodrigo Teodoro, Mathias Kranz, Matthias Scheunemann, Ute Egerland, Norbert Höfgen, Detlef Briel, Jörg Steinbach and 1 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Radiosynthesis and Preclinical Evaluation of a NovelACS medicinal chemistry letters · 2026
    Article
  2. Review
  3. Development ofInternational journal of molecular sciences · 2021
    Article
  4. PET Imaging of the Adenosine AMolecules (Basel, Switzerland) · 2020
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Susann SchröderDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany. s.schroeder@hzdr.de.ORCID 0000-0001-6440-1362
Barbara WenzelDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany. b.wenzel@hzdr.de.
Winnie Deuther-ConradDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany.ORCID 0000-0003-3168-3062
Rodrigo TeodoroDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany. r.teodoro@hzdr.de.
Mathias KranzDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany. m.kranz@hzdr.de.
Matthias ScheunemannDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany. m.scheunemann@hzdr.de.
Ute EgerlandBioCrea GmbH, Radebeul 01445, Germany. ute.egerland@outlook.de.
Norbert HöfgenBioCrea GmbH, Radebeul 01445, Germany. norbert.hoefgen@dynabind.com.
Detlef BrielPharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Faculty of Medicine, Leipzig University, Leipzig 04103, Germany. briel@uni-leipzig.de.
Jörg SteinbachDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany. j.steinbach@hzdr.de.ORCID 0000-0002-1708-6440
Peter BrustDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany. p.brust@hzdr.de.ORCID 0000-0001-5555-7058

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specific radioligands for in vivo visualization and quantification of cyclic nucleotide phosphodiesterase 2A (PDE2A) by positron emission tomography (PET) are increasingly gaining interest in brain research. Herein we describe the synthesis, the

Indexed as

AnimalsAutoradiographyBrainChromatography, LiquidCyclic Nucleotide Phosphodiesterases, Type 2Fluorine RadioisotopesImidazolesMiceMicrotomyMolecular ImagingNeuroimagingPositron-Emission TomographyProtein BindingPyridinesRadiopharmaceuticalsRatsCyclic Nucleotide Phosphodiesterases, Type 2Fluorine RadioisotopesImidazolesPde2a protein, ratPyridinesRadiopharmaceuticalsmetabolic stabilitymicellar liquid chromatography (MLC)neuroimagingPDE2A radioligandsPhosphodiesterase 2A (PDE2A)positron emission tomography (PET)secondary messengers

Identifiers

PMID29498659
PMCPMC6017663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.